CHEPLAPHARM acquired the commercial rights to PULMICORT FLEXHALER® in the US from AstraZeneca. PULMICORT FLEXHALER® is a well-established branded niche product for the treatment of asthma based on the active ingredient budesonide. The acquisition enables CHEPLAPHARM to further strengthen and diversify its portfolio and to increase its presence within the world’s largest pharmaceutical market.
PULMICORT FLEXHALER® was approved in the US in 2006 as prescription medication indicated for the maintenance treatment of asthma. Today, the product can look back on a successful track record with stable revenue streams and market position for more than a decade.
As a leading acquirer of originator brands from big pharma companies, CHEPLAPHARM has built up a strong and diversified portfolio of well-established medicines over the last 20 years. “With PULMICORT FLEXHALER® we acquire our first asthma medication and thus are able to further strengthen and diversify our portfolio”, says Edeltraud Lafer, CEO of CHEPLAPHARM. “At the same time, the transaction allows us to expand our footprint in the US, which is by far the largest pharmaceutical market in the world. In this context we are also looking forward to intensifying the cooperation with our highly experienced and trusted local distribution partner, enabling us to maintain the product’s successful positioning and ensure its continued availability for patients.”
The transaction includes product registrations, it does not include any transfer of manufacturing facilities or employees.
CHEPLAPHARM is a fast-growing pharmaceutical company, headquartered in Greifswald, Germany, offering branded and niche products worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy.
Please refer to www.cheplapharm.com for additional information.
CHEPLAPHARM ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ presse(at)cheplapharm.com